TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H.
( read original story …)